How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

931 results for

Human Papilloma Virus Vaccine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Knowledge, Decision-Making and Acceptance of Human Papilloma Virus Vaccination among Parents of Primary School Students in Kota Bharu, Kelantan, Malaysia Full Text available with Trip Pro

Knowledge, Decision-Making and Acceptance of Human Papilloma Virus Vaccination among Parents of Primary School Students in Kota Bharu, Kelantan, Malaysia Background: The incidence of cervical cancer in younger women remains high. This is worrisome as it affects future generations. Therefore Malaysia implements human papilloma virus (HPV) vaccination as a national vaccination program. Parents play an important role in determining the success of this HPV vaccination program among schoolaged girls (...) by their compliance. Objective: To assess parental knowledge, decision-making and acceptance of HPV vaccination. Methods: This cross sectional study was conducted among 280 randomly selected parents of primary school students aged 11 in Kota Bharu using a pre-validated self-administered questionnaire to assess knowledge and decision-making with regard to HPV vaccination. Results: Most parents (62%) were shown to have poor knowledge while most decision-making was shared. Age of respondents (adjusted odds ratio

2018 Asian Pacific journal of cancer prevention : APJCP

22. Genotype patterns and prevalence of human papilloma virus in non-vaccinated women in Zunyi, China Full Text available with Trip Pro

Genotype patterns and prevalence of human papilloma virus in non-vaccinated women in Zunyi, China To determine the patterns and prevalence of human papilloma virus (HPV) genotypes in people who are not vaccinated with HPV vaccines in Zunyi.We retrospectively collected all HPV testing results in 3,393 patients at the Third Affiliated Hospital in Zunyi Medical University, Zunyi, China between January 2014 and December 2016. The prevalence of HPV genotypes based on different stages of cervical (...) and HPV-68 in inpatients with pre-cancer and cancer lesions was one of the predominant findings. The coverage rates against cervical pre-cancer and cancer lesions for the 2 HPV vaccines, Cervarix was 35.4% and Gardasil 9 was 57%. Smoking and multiple pregnancy were more common in inpatients with HPV-16 and HPV-68 infection than those with other genotypes. Conclusions: Human papilloma virus-16 and HPV-68 are the 2 most prevalent and high-risk HPV genotypes in non-vaccinated women in Zunyi, which may

2018 Saudi medical journal

23. Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus Full Text available with Trip Pro

Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus Human papillomavirus (HPV) is a viral infection with skin-to-skin based transmission mode. HPV annually caused over 500,000 cancer cases including cervical, anogenital and oropharyngeal cancer among others. HPV vaccination has become a public-health concern, worldwide, to prevent the cases of HPV infections including precancerous lesions, cervical cancers, and genital warts (...) especially in adolescent female and male population by launching national programs with international alliances. Currently, available prophylactic and therapeutic vaccines are expensive to be used in developing countries for vaccination programs. The recent progress in immunotherapy, biotechnology, recombinant DNA technology and molecular biology along with alternative and complementary medicinal systems have paved novel ways and valuable opportunities to design and develop effective prophylactic

2018 Frontiers in immunology

24. Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl Full Text available with Trip Pro

Amyotrophic Lateral Sclerosis after Receiving the Human Papilloma Virus Vaccine: A Case Report of a 15-year-old Girl We herein report a 15-year-old girl who developed rapid progressive muscle weakness soon after the third injection of a bivalent human papilloma virus (HPV) vaccine. Although immunotherapies were performed for possible vaccine-related disorders, she died of respiratory failure 14 months after the onset of the disease. A genetic analysis identified a heterozygous p.P525L mutation (...) of the fused in sarcoma (FUS) gene, and a histopathological analysis was also consistent with FUS-associated amyotrophic lateral sclerosis (ALS) without any evidence of neuroinflammation. We concluded the diagnosis to be FUS-ALS, although we cannot completely rule out the possibility that the vaccination worked as a trigger.

2018 Internal Medicine

25. Human papilloma virus vaccination against cervical cancer in adult women: a systematic review and meta-analysis

Human papilloma virus vaccination against cervical cancer in adult women: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) . No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data

2020 PROSPERO

26. Randomized controlled trials to improve Human Papilloma Virus vaccine uptake in the United States: A systematic review with meta-analysis

Randomized controlled trials to improve Human Papilloma Virus vaccine uptake in the United States: A systematic review with meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) . Not an in vivo animal study 3. No metastases/ only primary tumor 4. No control group 5. Combination therapy or contamination 6. Not about analgesics used in the clinic Full text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital

2020 PROSPERO

27. Human papilloma virus and lupus: the virus, the vaccine and the disease. (Abstract)

Human papilloma virus and lupus: the virus, the vaccine and the disease. Systemic lupus erythematosus (SLE) is a well known, widespread autoimmune disease, involving multiple organ systems, with a multifaceted, widely unmapped etiopathogenesis. Recently, a new aspect of morbidity has been described among SLE patients: infection with human papilloma virus (HPV). We set out to review data regarding the intricate relationship between the two and attempt to determine whether HPV may pose (...) of immune cross-reaction due to molecular homology.We review clinical, epidemiological and molecular data suggesting involvement of HPV infection in the pathogenesis of SLE. We suggest that these findings may justify the development of new HPV vaccines containing viral peptides that bear no homology to the human proteome, in order to avoid possible adverse immune cross-reactivity.

2017 Current Opinion in Rheumatology

28. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. (Abstract)

Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers. Treatments for gynecological cancer include surgery, chemotherapy, and radiation. However, overall survival is not improved, and novel approaches are needed. Immunotherapy has been proven efficacious in various types of cancers and multiple approaches have been recently developed. Since numerous gynecological cancers are associated to human papilloma virus (HPV) infections, therapeutic vaccines, targeting (...) cancers. The synergic results obtained from the combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, or immune checkpoint inhibitors, may underlie the potential for a novel therapeutic scenario for these tumors.Copyright © 2018 Elsevier B.V. All rights reserved.

2018 Critical reviews in oncology/hematology

29. Increasing HPV Immunization Rates: The Rural Adolescent Vaccine Enterprise

. Condition or disease Intervention/treatment Phase Human Papilloma Virus Behavioral: Practice facilitation Not Applicable Detailed Description: The overarching goal of this study is to engage rural primary care clinics and community organizations to test interventions designed to increase HPV vaccinations in both male and female patients aged 9-26 years. Using a step-wedge randomized controlled trial, we will design and test the effectiveness of multi-component primary care practice-based interventions (...) : 22000 participants Allocation: Randomized Intervention Model: Crossover Assignment Intervention Model Description: Aims II and III are interventional, using a randomized stepped-wedge design with the practice as the unit of randomization. Masking: None (Open Label) Primary Purpose: Health Services Research Official Title: Increasing Human Papillomavirus (HPV) Immunization Rates: The Rural Adolescent Vaccine Enterprise (RAVE) Actual Study Start Date : September 19, 2018 Estimated Primary Completion

2018 Clinical Trials

30. Human Papilloma Virus immunity in oropharyngeal cancer: time to change the game? Full Text available with Trip Pro

Human Papilloma Virus immunity in oropharyngeal cancer: time to change the game? For the first time, human papillomavirus (HPV)-specific immunity has been linked directly to the beneficial prognosis of oropharyngeal squamous cell carcinoma (OPSCC). Those patients lacking HPV immunity fare much worse. These results harbor crucial implications for future management of HPV-driven OPSCC as well as for its definition. Clin Cancer Res; 24(3); 505-7. ©2017 AACRSee related article by Welters et al., p

2017 Clinical Cancer Research

31. Immune Modulation and Treatment of Human Papilloma Virus-Related Warts with Energetics of Living Systems Acupuncture Full Text available with Trip Pro

Immune Modulation and Treatment of Human Papilloma Virus-Related Warts with Energetics of Living Systems Acupuncture Background: Cutaneous warts are small skin lesions formed as a result of infection by the human papilloma virus (HPV). In the lesion, viral manipulation creates a microenvironment that favors virus survival and reproduction. Most lesions eventually regress, probably as a result of a Th1-mediated immune response. However, some warts fail to regress and become persistent. Objective (...) : The efficacy of treatment of persistent HPV-caused warts with Energetics of Living Systems acupuncture and monitored immune system involvement was tested. Methods: Eighteen patients with persistent warts were recruited for the study; 9 received acupuncture treatment and 9 received placebo. Each patient was treated 4 times. Results: Clinical success was defined as total clearance of all lesions with no recurrence for 3 months. In the treatment group, clinical success was 36.6% versus 0% in the placebo group

2017 Medical Acupuncture Controlled trial quality: uncertain

32. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Full Text available with Trip Pro

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Safety of HPV vaccines is still in question due to reports of autoimmune diseases (ADs) following HPV immunization.To assess the risk of ADs associated with HPV vaccination of female adolescents/young adults in France.Systematic prospective case-referent study conducted to assess the risks associated with real-life use of HPV vaccines. Cases were female 11-25 years old with incident (...) ADs [central demyelination/multiple sclerosis (CD/MS), connective tissue disease (CTD), Guillain-Barré syndrome (GBS), type-1 diabetes (T1D), autoimmune thyroiditis (AT), and idiopathic thrombocytopenic purpura (ITP)]. Cases were consecutively and prospectively identified at specialized centers across France (2008-2014) and individually matched by age and place of residence to referents recruited in general practice. Risk was computed using multivariate conditional logistic regression models

2017 Journal of Autoimmunity

33. Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination

Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03350698 Recruitment Status : Not yet recruiting First Posted : November 22, 2017

2017 Clinical Trials

34. Improving Human Papilloma Virus Vaccination Rates: Quality Improvement Full Text available with Trip Pro

Improving Human Papilloma Virus Vaccination Rates: Quality Improvement Human papilloma virus (HPV) is a sexually transmitted infection with a national prevalence of greater than 70 million. Most infections are among persons 15-24 years of age. The HPV vaccine has nearly 100% efficacy when administered before natural exposure. However, national vaccination rates remain less than 50%. Our objective was to improve the rate of initiation of the HPV vaccination series in a resident teaching (...) practice.We used the Plan Do Study Act methodology for quality improvement. Eligible patients included children 9 through 13 years of age who presented to a general pediatric clinic. We established baseline data by reviewing HPV immunization rates taken from a convenience sample of ≤20 patients per month over 7 months. A key driver diagram guided interventions including resident communication, nursing staff education, family knowledge, and an electronic medical record prompt beginning at age 9. Using

2017 Pediatric Quality & Safety

35. Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus Full Text available with Trip Pro

Combining agent based-models and virtual screening techniques to predict the best citrus-derived vaccine adjuvants against human papilloma virus Human papillomavirus infection is a global social burden that, every year, leads to thousands new diagnosis of cancer. The introduction of a protocol of immunization, with Gardasil and Cervarix vaccines, has radically changed the way this infection easily spreads among people. Even though vaccination is only preventive and not therapeutic (...) , it is a strong tool capable to avoid the consequences that this pathogen could cause. Gardasil vaccine is not free from side effects and the duration of immunity is not always well determined. This work aim to enhance the effects of the vaccination by using a new class of adjuvants and a different administration protocol. Due to their minimum side effects, their easy extraction, their low production costs and their proven immune stimulating activity, citrus-derived molecules are valid candidates

2017 BMC bioinformatics

36. Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage. Full Text available with Trip Pro

Cost-effectiveness of Human Papilloma Virus (HPV) vaccination in Nigeria: a decision analysis using pragmatic parameter estimates for cost and programme coverage. World Health Organisation recommends routine Human Papilloma Virus (HPV) vaccination for girls when its cost-effectiveness in the country or region has been duly considered. We therefore aimed to evaluate cost-effectiveness of HPV vaccination in Nigeria using pragmatic parameter estimates for cost and programme coverage, i.e (...) . realistically achievable in the studied context.A microsimulation frame-work was used. The natural history for cervical cancer disease was remodelled from a previous Nigerian model-based study. Costing was based on health providers' perspective. Disability adjusted life years attributable to cervical cancer mortality served as benefit estimate. Suitable policy option was obtained by calculating the incremental costs-effectiveness ratio. Probabilistic sensitivity analysis was used to assess parameter

2017 BMC health services research

37. Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18 Full Text available with Trip Pro

Epitope design of L1 protein for vaccine production against Human Papilloma Virus types 16 and 18 Cervical cancer accounts for about two-thirds of all cancer cases linked etiologically to Human Papilloma Virus (HPV). 15 oncogenic HPV types can cause cervical cancer, of which HPV16 and HPV18 combinedly account for about 70% of it. So, effective epitope design for the clinically relevant HPV types 16 and 18 would be of major medical benefit. Here, a comprehensive analysis is carried out (...) and 18. We had selected HLA-A*0201, DRB1*1501, DQB1*0602, DRB1*0401 and DQB1*0301 alleles for the prediction of T cell epitopes of L1 of HPV 16 and 18. Finally, we reported that predicted epitope sequences EEYDLQFIFQLCKITLTA, and RHGEEYDLQFIFQLCKITLTA of L1 protein of HPV 16, and LPDPNKF, PETQRLVWAC, PVPGQYDA, YNPETQRLVWAC, DTGYGAMD, PVPGQYDATK, KQDIPKVSAYQYRVFRV, RDNVSVDYKQTQLCI and YSRHVEEYDLQFIF of L1 protein of HPV 18 could be therapeutic tools for vaccine design against HPV.

2017 Bioinformation

38. Multimodal Counseling Interventions: Effect on Human Papilloma Virus Vaccination Acceptance Full Text available with Trip Pro

Multimodal Counseling Interventions: Effect on Human Papilloma Virus Vaccination Acceptance Human papilloma virus (HPV) vaccine was developed to reduce HPV-attributable cancers, external genital warts (EGW), and recurrent respiratory papillomatosis. Adolescent HPV vaccination series completion rates are less than 40% in the United States of America, but up to 80% in Australia and the United Kingdom. Population-based herd immunity requires 80% or greater vaccination series completion rates. Pro (...) -vaccination counseling facilitates increased vaccination rates. Multimodal counseling interventions may increase HPV vaccination series non-completers' HPV-attributable disease knowledge and HPV-attributable disease prophylaxis (vaccination) acceptance over a brief 14-sentence counseling intervention. An online, 4-group, randomized controlled trial, with 260 or more participants per group, found that parents were more likely to accept HPV vaccination offers for their children than were childless young

2017 Healthcare Controlled trial quality: uncertain

39. Human papilloma virus vaccine for low and middle income countries: A step too soon? Full Text available with Trip Pro

Human papilloma virus vaccine for low and middle income countries: A step too soon? Cervical Cancer is the most common genital cancer in women in India. Human papilloma virus (HPV) causes precancerous lesions that often develop into cervical cancer suggesting that cervical cancer has an infective etiology and is potentially preventable by preventing HPV infection through the use of HPV vaccines. The incidence in developing nations is largely under-reported due to large population size, poor (...) and incomplete database. HPV vaccine is being considered for inclusion in the immunization schedule of developing countries. An effective surveillance system for a vaccine requires that the baseline incidence, prevalence, and mortality rates of cervical cancer are established for a given population. The lessons learnt from the polio vaccine must be applied to every vaccine being introduced for its optimal utilization. HPV vaccines might be used as a cost-effective scientific intervention to prevent cervical

2017 Human vaccines & immunotherapeutics

40. Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region Full Text available with Trip Pro

Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region This commentary explores the distribution of human papilloma virus (HPV) and HPV-related diseases, and factors affecting attitudes towards HPV, HPV-related diseases, and HPV vaccination in the Latin American Andean region. Lack of knowledge of HPV, known negative attitudes or incorrect assumptions about HPV, HPV-related diseases, and HPV vaccination provide a basis upon which to develop targeted HPV (...) awareness and preventive health media campaigns. For maximal effect, media campaigns should use the internet, radio, and television to address health care providers, parents, and students. Additional programming can be developed for clinics to use in-house with their clients. Ministries of Education, Finance, and Health all have roles to play to increase national HPV, HPV-related diseases, and HPV vaccination awareness.

2017 Healthcare

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>